Rapid-Infusion Rituximab in Lymphoma Treatment: 2-Year Experience in a Single Institution


Atay S., BARIŞTA İ. , GÜNDOĞDU F. , Akgedik K., Arpaci A.

JOURNAL OF ONCOLOGY PRACTICE, cilt.8, ss.141-143, 2012 (ESCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 8 Konu: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1200/jop.2011.000319
  • Dergi Adı: JOURNAL OF ONCOLOGY PRACTICE
  • Sayfa Sayıları: ss.141-143

Özet

Purpose: Rituximab is a chimeric anti-CD20 monoclonal antibody. We aimed to explore the safety and tolerability of rapid infusion rituximab, (over 90 minutes) in patients with non-Hodgkin's lymphoma at Hacettepe University Department of Medical Oncology.